Browse the evidence

Obesity prevalence is projected to grow by 40% in the next decade.

Health professionals should prepare for increased obesity-related health issues.

Meta-analysis is commonly used in sport and exercise science to synthesize empirical studies.

Practitioners should consider using meta-analysis to inform their understanding of empirical studies.

Loss-of-function mutations in the genes encoding POMC, MC3R, and MC4R can lead to early-onset obesity and developmental dysregulation.

Understanding these mutations can inform treatment strategies for obesity.

1,260,969 (8.5%) Black people and 4,989,919 (4.7%) non-Black people had ≥CKD stage 3 according to the 2021 CKD-EPI formula.

Practitioners should consider the impact of the new eGFR formula on the classification of CKD in patients when prescribing antiobesity medications.

Obesity affects around 40% of adults in the United States.

Health practitioners should be aware of the high prevalence of obesity in the adult population.

Obesity accounts for $172.74 billion in annual expenditures in the United States.

Understanding the economic burden of obesity can inform healthcare policy and resource allocation.

Obesity alone did not emerge as a robust predictor of major adverse cardiovascular events (MACEs).

Obesity should not be solely relied upon as a risk factor in cardiovascular assessments.

The effectiveness of nutrigenomics and lifestyle genomics interventions for weight management in clinical practice cannot yet be conclusively determined.

Practitioners should be cautious in applying nutrigenomic interventions for weight management until more conclusive evidence is available.

Current dietary practices reflect thousands of years of an almost Darwinian process of natural selection.

Understanding the historical context of dietary practices can inform current dietary recommendations.

More basic and applied research is needed to identify food consumption trends.

Increased research efforts can lead to better dietary policies and health outcomes.

Nitro-oleic acid treatment does not alter body weight in Nrf2fl/fl and ANKO mice on both high fat diet (HFD) and low-fat diet (LFD).

NO2-OA may not affect body weight, suggesting its effects are more focused on metabolic parameters rather than weight loss.

Obesity is defined as a body mass index of ≥30 kg/m² (≥27 kg/m² for those of Asian descent).

Practitioners should use these BMI thresholds for diagnosing obesity.

Section 1115 Demonstration Waivers are currently serving as a temporary funding mechanism for nutrition-related programs.

Understanding the temporary nature of current funding can inform program planning.

Approximately 83.0% of patients in both treatment groups receive TSH testing within a 1-year follow-up.

Practitioners should note that a high percentage of older adults on levothyroxine are monitored for TSH after initiating GLP-1 RAs.

TSH testing patterns did not differ between GLP-1 RAs and SGLT-2is.

Clinicians can expect similar TSH monitoring practices regardless of whether patients are on GLP-1 RAs or SGLT-2is.

The mean time to TSH testing was approximately 130.5 days for both groups.

Practitioners should be aware that TSH testing occurs on average about 130 days after treatment initiation.

Future research should standardize economic evaluation methods in SET studies for better comparison across diverse interventions, settings, and populations.

Researchers should aim for consistent evaluation methods to enhance the validity of findings in SET studies.

No significant findings emerged in White women, African American men, or for the 8-10 week outcomes regarding WCadjBMI or WHRadjBMI.

Results may not be generalizable to all demographic groups, indicating the need for tailored approaches in interventions.

Mean total costs per person-year decreased from $5227.25 to $4982.88 over three years.

Cost management strategies may be effective in obesity care over time.

Obesity has increased from 30.5% during 1999–2000 to 41.9% during 2017–2020.

Health practitioners should be aware of the rising obesity rates when designing interventions.

There is significant societal attention on the issues of overweight and obesity.

Practitioners should be aware of the societal context when addressing obesity in patients.

There was no significant difference in the cost of diabetes therapy between the two groups (p = 0.12).

Practitioners can consider that an open formulary may improve glycemic control without increasing costs.

More studies are needed to provide conclusive results on the efficacy of eHealth interventions.

Continued research is essential for validating the effectiveness of eHealth interventions.

More studies are needed to provide conclusive results on the efficacy of eHealth interventions.

Future research is essential to validate the effectiveness of eHealth interventions.